Clinical efficacy of potassium canreonate-canrenone in sinus rhythm restoration among patients with atrial fibrillation - a protocol of a pilot, randomized, double -blind, placebo-controlled study (CANREN-AF trial)
Authors:
- Rafał DąbrowskiRDRafał Dąbrowski
- Paweł SyskaPSPaweł Syska
- Justyna MączyńskaJMJustyna Mączyńska
- Michał FarkowskiMFMichał Farkowski
- Stefan SawickiSSStefan Sawicki
- Agata Kubaszek-KornatowskaAKAgata Kubaszek-Kornatowska
- Piotr MichałekPMPiotr Michałek
- Ilona KowalikIKIlona Kowalik
- Hanna SzwedHSHanna Szwed
- Tomasz HryniewieckiTHTomasz Hryniewiecki
Open Access
- 12 May 2020
- journal article
- research article
- Published by Springer Nature in Trials
- Vol. 21 (1) , 1-7
Abstract
Background: Atrial fibrillation (AF) is the most frequent cardiac arrhythmia which increases the risk of thromboembolic complications and impairs quality of life. An important part of a therapeutic approach for AF is sinus rhythm restoration. Antiarrhythmic agents used in pharmacological cardioversion have limited efficacy and potential risk of proarrhythmia. Simultaneously, underlying conditions of AF should be treated (e.g. electrolyte imbalance, increased blood pressure, neurohormonal disturbances, atrial volume overload). There is still the need for an effective and safe approach to increase AF cardioversion efficacy. This randomized, double-blind, placebo-controlled, superiority clinical study is performed in patients with AF in order to evaluate the clinical efficacy of intravenous canrenone in sinus rhythm restoration. Methods: Eighty eligible patients with an episode of AF lasting less than 48 h are randomized in a 1:1 ratio to receive canrenone or placebo. Patients randomized to a treatment intervention are receiving canrenone intravenously at a dose of 200 mg within 2–3 min. Subjects assigned to a control group obtain the same volume of 0.9% saline within the same time. The primary endpoint includes return of sinus rhythm documented in the electrocardiogram within 2 h after drug or placebo administration. Other endpoints and safety outcomes analyses, due to expected lack of statistical power, are exploratory. Discussion: Current evidence supports renin–angiotensin–aldosterone system (RAAS) inhibition as an upstream therapy in AF management. Excess aldosterone secretion results in proarrhythmic effects. Among the RAAS inhibitors, only canrenone is administered intravenously. Canrenone additionally increases the plasma level of potassium, lowers blood pressure and reduces preload. It has been already used in primary and secondary hyperaldosteronism in the course of chronic liver dysfunction and in heart failure. Trial registration: ClinicalTrials.gov, NCT03536806. Registered on 25 May 2018.Keywords
Funding Information
- National Institute of Cardiology (2.62/VII/16)
This publication has 14 references indexed in Scilit:
- 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive SummaryCirculation, 2014
- Increased Plasma Aldosterone during Atrial Fibrillation Declines following CardioversionCardiology, 2011
- Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary preventionEP Europace, 2011
- Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part II: secondary preventionEP Europace, 2011
- Effect of Combined Spironolactone–β-Blocker ± Enalapril Treatment on Occurrence of Symptomatic Atrial Fibrillation Episodes in Patients With a History of Paroxysmal Atrial Fibrillation (SPIR-AF Study)The American Journal of Cardiology, 2010
- Usefulness of Vernakalant Hydrochloride Injection for Rapid Conversion of Atrial FibrillationThe American Journal of Cardiology, 2010
- A multicenter, open-label study of vernakalant for the conversion of atrial fibrillation to sinus rhythmAmerican Heart Journal, 2010
- A Decrease in Serum Aldosterone Level is Associated with Maintenance of Sinus Rhythm after Successful Cardioversion of Atrial FibrillationPacing and Clinical Electrophysiology, 2010
- Vernakalant Hydrochloride for Rapid Conversion of Atrial FibrillationCirculation, 2008
- CANRENONE—THE PRINCIPAL ACTIVE METABOLITE OF SPIRONOLACTONE?British Journal of Clinical Pharmacology, 1976